Back to search
FDAFDA · Food and drugs·Recall number D-0203-2025

Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-079-93

Published January 22, 2025 · Recall initiated: December 23, 2024

Summary

FDA records drug Class II recall D-0203-2025, published January 22, 2025 and initiated December 23, 2024. Recalling firm: Viatris Inc; Status: Terminated; Reported quantity: 1,215/30 count bottles; Lot: Lot # 8181625, Exp 12/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if CARDURA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CARDURA
Manufacturer
Viatris Inc
Distributor
USA nationwide.
UPC
0358151078936
Lot
Lot # 8181625, Exp 12/31/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-079-93 recalled?

Yes. FDA published recall D-0203-2025 on January 22, 2025. Reported hazard: Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CARDURA. UPC: 0358151078936.